Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海君实生物医药科技股份有限公司主营业务为新药的研发及相关技术的转让和服务,新药的生产和销售,其主要产品与服务项目单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术转让等。公司提供的技术服务指利用技术平台为客户提供定制服务,包括分子序列的设计及改造、高表达细胞株的构建、小试及中试工艺研究、临床前研究及临床研究样品的制备等。公司为第一家获得NMPA的抗PD-1单克隆抗体上市批准的中国公司。国内首个获批临床的抗PCSK9单抗、全球首个获批临床的抗BTLA单抗和首个在欧美等海外国家及地区获得紧急使用授权（EUA）的国产COVID-19治疗药物埃特司韦单抗。
Main Business 新药的研发及相关技术的转让和服务，新药的生产和销售
Legal Representative 熊俊
Top Executives
董事长：熊俊
副董事长：NING LI
执行董事：李聪,GANG WANG（王刚）,熊俊,NING LI,SHENG YAO,张卓兵,邹建军
非执行董事：李鑫,汤毅,冯辉
独立董事：孟安明,张淳,钱智,Roy Steven Herbst
独立非执行董事：冯晓源
Top 5 Shareholder
Shareholder name Nature Holding Date
HKSCC NOMINEES LIMITEDH股22.25%31/03/2024
熊俊流通A股8.91%31/03/2024
上海檀英投资合伙企业（有限合伙）流通A股7.77%31/03/2024
苏州瑞源盛本生物医药管理合伙企业（有限合伙）流通A股4.42%31/03/2024
熊凤祥流通A股4.17%31/03/2024
Company Secretary 陈英格
Solicitors 北京市嘉源律师事务所
Auditors 容诚会计师事务所（特殊普通合伙）
Tel No 021-22500300-1153
Fax No 021-6175-7377
Website www.junshipharma.com
Email Info@junshipharma.com
Company Address
Register: 中国（上海）自由贸易试验区海趣路36、58号2号楼10层1003室
Office: 上海市浦东新区平家桥路100弄6号7幢16层
Listing Date 15/07/2020
Shares Capital
Shares Capital: 985,689,871
Total A Share: 766,394,171
Listed A Share: 762,837,471
Non-tradable A Share: 3,556,700
Other Share: 0
Total B Share: 0
Total H Share: 219,295,700
EPS(RMB)* ¥ -2.320
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 7.260
Market Capitalization(RMB) 22.664B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.